Dynavax Technologies (NASDAQ:DVAX) Upgraded to Buy at StockNews.com

by · The Markets Daily

StockNews.com upgraded shares of Dynavax Technologies (NASDAQ:DVAX – Free Report) from a hold rating to a buy rating in a report published on Monday.

Several other research firms also recently issued reports on DVAX. William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. HC Wainwright reissued a “buy” rating and set a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and reduced their target price for the company from $15.00 to $12.00 in a report on Tuesday, February 11th.

Get Our Latest Report on DVAX

Dynavax Technologies Stock Performance

Shares of DVAX opened at $13.69 on Monday. The stock has a 50 day moving average of $12.84 and a 200 day moving average of $12.07. The company has a market capitalization of $1.70 billion, a price-to-earnings ratio of 76.06 and a beta of 1.32. Dynavax Technologies has a 12 month low of $9.74 and a 12 month high of $14.05. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX – Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The firm had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. As a group, sell-side analysts forecast that Dynavax Technologies will post 0.32 earnings per share for the current year.

Institutional Trading of Dynavax Technologies

Several large investors have recently modified their holdings of DVAX. E Fund Management Co. Ltd. grew its holdings in shares of Dynavax Technologies by 4.6% during the 4th quarter. E Fund Management Co. Ltd. now owns 17,627 shares of the biopharmaceutical company’s stock worth $225,000 after acquiring an additional 771 shares during the period. Summit Investment Advisors Inc. boosted its position in shares of Dynavax Technologies by 7.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 13,782 shares of the biopharmaceutical company’s stock valued at $176,000 after purchasing an additional 904 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock worth $83,000 after purchasing an additional 1,076 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in Dynavax Technologies by 6.3% in the fourth quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock worth $245,000 after purchasing an additional 1,109 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 1,169 shares during the period. 96.96% of the stock is owned by institutional investors.

About Dynavax Technologies

(Get Free Report)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Read More